National guidelines are clear that children hospitalized with influenza should receive antiviral treatment. In practice, use of those drugs among hospitalized children has been falling. A large study published in JAMA Pediatrics offers fresh evidence that the guidelines are right.
Children hospitalized with flu who received the antiviral oseltamivir early were 31 percent less likely to be admitted to an intensive care unit than those who did not get it, and they had shorter hospital stays. The University of Colorado Anschutz, which led the work, describes it as the largest real-world study of its kind.
The findings arrive after one of the most severe flu seasons in roughly two decades, said Suchitra Rao, a professor of pediatrics at the University of Colorado Anschutz School of Medicine, an infectious disease specialist at Children’s Hospital Colorado and the study’s senior author. They show, she said, that “oseltamivir treatment can decrease the risk of needing critical care.”
7,000 Hospitalizations, Eight Flu Seasons
The researchers drew on more than 7,000 pediatric hospitalizations recorded in FluSurv-NET, a surveillance network supported by the U.S. Centers for Disease Control and Prevention that tracks laboratory-confirmed influenza hospitalizations. The data spanned 13 states and eight flu seasons between 2014 and 2023.
Oseltamivir, sold under the brand name Tamiflu, is the most widely used flu antiviral. It works best when given soon after symptoms begin, which has fueled doubts about its value for children who are already sick enough to need a hospital bed, often several days into their illness.
Accounting for Timing
That question of timing is where this study departs from many earlier ones. Previous observational research often lacked reliable information on when a child’s symptoms started and when treatment began, Rao said. This analysis accounted for both and applied advanced statistical methods to produce stronger real-world evidence.
The results suggest the drug helps even when started later than ideal. According to Rao, oseltamivir may reduce the need for critical care even when treatment begins more than two days into the illness. Her message for clinicians is direct: children hospitalized with influenza should be treated.
The authors say the findings reinforce current national recommendations that hospitalized children with suspected or confirmed influenza receive an antiviral as soon as possible.
What an Observational Study Can Say
The study is observational, not a randomized trial, so it shows an association between treatment and better outcomes rather than proving that the drug caused them. Children who received oseltamivir may have differed in other ways from those who did not, and statistical adjustment can reduce that problem without eliminating it. The university’s summary does not report absolute risks or how much shorter hospital stays were, and while the headline calls the study the largest of its kind, the body of the summary describes it more modestly as one of the most comprehensive.
Randomized trials in hospitalized children are difficult to run when guidelines already recommend treatment, which is why large, carefully adjusted real-world analyses like this one carry weight. Parents with questions about a child’s flu treatment should talk with the child’s doctor.
Endnotes
- “Effectiveness of Oseltamivir in Hospitalized Children with Laboratory-Confirmed Influenza, 2014-2023.” (2026). JAMA Pediatrics. Senior author Suchitra Rao.
- University of Colorado Anschutz (August 10, 2026). “Largest real-world study finds early flu antiviral treatment reduces ICU admissions in hospitalized children.” EurekAlert! https://www.eurekalert.org/news-releases/1139445




Leave a Reply